HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis
HRR-guided talazoparib plus enzalutamide does not appear to be cost-effective for mCRPC patients from the U.S. payer perspective.
Authors
- Mingjun Rui (ORCID: https://orcid.org/0000-0001-8649-6454)
- Yingcheng Wang (ORCID: https://orcid.org/0000-0002-1784-4504)
- Joyce H. S. You (ORCID: https://orcid.org/0000-0002-5763-7403)
- Qiran Wei (ORCID: https://orcid.org/0000-0002-0261-6381)
Institutions
- Chinese University of Hong Kong (HK)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251356109
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05